Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET).
A Phase IV, Prospective, Randomized, Open-label, Active-controlled, Parallel-group, Multicenter Study to Evaluate Efficacy and Safety of Fang Le Shu (Recombinant FSH) Versus Guo Na Fen Used for Controlled Ovarian Stimulation in Infertile Women Undergoing In Vitro Fertilization-Embryo Transfer.
LG Chem
248 participants
Feb 15, 2025
INTERVENTIONAL
Conditions
Summary
The aim of this randomized, open-label, active-controlled, parallel-group, multicenter, phase IV study is to assess the efficacy and safety of Fang Le Shu versus Guo Na Fen used for controlled ovarian stimulation in infertile women undergoing In Vitro Fertilization-Embryo Transfer.
Eligibility
Inclusion Criteria5
- Is pre-menopausal female aged ≥20 to <40 years.
- Has regular menstrual cycles of ≥25 to ≤35 days.
- Has Normal baseline serum FSH, LH, E2, P4.
- Is able to voluntarily sign the informed consent form (ICF).
- Has history of infertility for at least 1 year before the day of randomization; however, subjects with confirmed diagnosis of infertility are eligible without fulfilling the 1-year requirement.
Exclusion Criteria12
- Has any known clinically significant major systemic disease, or endocrine or metabolic abnormalities with the exception of controlled thyroid function disease.
- Has body mass index (BMI) of >30 kg/m2.
- Has clinically significant abnormalities of the uterus, ovary, or appendix prior to the day of randomization
- Has history of surgeries that may affect oocyte retrieval or pregnancy outcome, such as surgical resection of uterine mediastinum, fibroids, or cysts (however, patients who received polypectomy are allowed to enroll).
- Has history of severe ovarian hyperstimulation syndrome (OHSS) defined as Grade 4 or higher.
- Poor ovarian reponder according to Bologna criteria
- Has plans to donate oocyte or recieve embryo from another women or undergo preimplantation genetic testing(PGT)
- Has history of three or more failures in previous IVF cycles
- Has history of recurrent miscarriage
- Has known current active pelvic inflammatory disease.
- Is currently breastfeeding.
- Has a contraindication to pregnancy that would preclude participation in the trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
rFSH 150 IU, 225 IU, 300 IU per syringe
rFSH 450 IU per pen
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06921395